| Name | IDF-11774 |
| Description | IDF-11774 is a HIF-1 inhibitor.It reduces hif-1α HRE luciferase activity (IC50 = 3.65 μM). |
| Animal Research | When IDF-11774 is orally administered daily for two weeks, significant dose-dependent tumor regression is observed in the mouse model. |
| In vitro | IDF-11774 treatment suppressed angiogenesis of cancer cells by reducing the expression of HIF-1 target genes, reduced glucose uptake, thereby sensitizing cells to growth under low glucose conditions, and decreased the extracellular acidification rate (ECAR) and oxygen consumption rate of cancer cells. |
| In vivo | Luciferase activity and HIF-1α accumulation are significantly suppressed in the tumors of mice treated with oral administration of IDF-11774, compared to the control. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 19.23 mg/mL (52.18 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.71 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | IDF-11774 | IDF11774 | IDF 11774 | Hypoxia-inducible factors | HIFs | HIFProlylHydroxylase | HIF-PH | HIF-1α | HIF/HIFProlylHydroxylase | HIF/HIF Prolyl-Hydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF |
| Inhibitors Related | Deferoxamine Mesylate | Hydralazine hydrochloride | Dapagliflozin | Glucosamine | Hydroxycitric acid tripotassium hydrate | Glucosamine hydrochloride | Chloramphenicol | Oroxylin A | Acriflavine Hydrochloride | Albendazole | Glucosamine sulfate | Cinnamaldehyde |
| Related Compound Libraries | Reprogramming Compound Library | Glycolysis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | HIF-1 Signaling Pathway Compound Library | Epigenetics Compound Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
